Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

15.36
+0.01000.07%
Pre-market: 15.13-0.2300-1.50%07:00 EDT
Volume:11.33M
Turnover:172.98M
Market Cap:17.60B
PE:-10.59
High:15.46
Open:15.38
Low:15.02
Close:15.35
Loading ...

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
06 Mar

Teva price target lowered to $20 from $23 at BofA

TIPRANKS
·
06 Mar

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Teva Pharmaceutical (TEVA) and Incyte (INCY)

TIPRANKS
·
06 Mar

BRIEF-Teva Launches Spring Summer 2025 Collection Designed For Playground Earth

Reuters
·
04 Mar

Teva Launches Spring Summer 2025 Collection; Designed for Playground Earth

THOMSON REUTERS
·
04 Mar

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

GlobeNewswire
·
04 Mar

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Is Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts?

Insider Monkey
·
02 Mar

Sanofi's Positive Duvakitug Data Raises Market Questions for Teva Pharmaceutical Industries (NYSE:TEVA)

Simply Wall St.
·
02 Mar

Is Teva Pharmaceutical Industries Limited (TEVA) the Best Low Price Pharma Stock to Invest In Right Now?

Insider Monkey
·
27 Feb

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

THOMSON REUTERS
·
27 Feb

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

GlobeNewswire
·
27 Feb

Teva, Medincell announce FDA acceptance of sNDA for Uzedy

TIPRANKS
·
26 Feb

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

GlobeNewswire
·
26 Feb

Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks

Insider Monkey
·
26 Feb

Teva Pharmaceutical’s Promising TL1a Program Drives Buy Rating Amid Strong Phase 2 Data for Duvakitug

TIPRANKS
·
25 Feb